John Dietrich
Keine laufenden Positionen mehr
Vermögen: 177 395 $ am 31.03.2024
Ursprung des Netzwerks ersten Grades von John Dietrich
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.
13
| Extinct | Miscellaneous Commercial Services | 13 |
| Private Company | Pharmaceuticals: Major | 8 | |
Ventrus Biosciences, Inc.
 Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY.
3
| Extinct | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von John Dietrich
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Cygnus, Inc.
 Cygnus, Inc. Medical SpecialtiesHealth Technology Cygnus, Inc. develops and manufactures glucose-monitoring devices. The company develops devices that provide data to individuals and physicians to enable them to manage diabetes. It was founded in 1985 and is headquartered in San Francisco, CA. | Medical Specialties | Corporate Officer/Principal | |
| APTOSE BIOSCIENCES INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
| QUESTCOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
| DURECT CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
DNA Sciences, Inc.
 DNA Sciences, Inc. Medical SpecialtiesHealth Technology Part of AbbVie, Inc., DNA Sciences, Inc. is a private company that develops and produces in vitro diagnostic and research reagent products. The company is based in Fremont, CA. The company was founded by Hugh Young Rienhoff. DNA Sciences was acquired by Genaissance Pharmaceuticals, Inc., part of AbbVie, Inc. from October 07, 2005 on April 01, 2003 for $1.30 million. | Medical Specialties | Director of Finance/CFO | |
| ONCOLYTICS BIOTECH INC. | Biotechnology | Director/Board Member | |
| SERNOVA CORP. | Biotechnology | Director/Board Member | |
| TIMMINCO LIMITED | Metal Fabrication | Comptroller/Controller/Auditor | |
| TRILLIUM THERAPEUTICS | Biotechnology | Director/Board Member President Director of Finance/CFO Corporate Officer/Principal | |
Abmaxis, Inc.
 Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Corporate Officer/Principal | |
| DIAMEDICA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Chairman Chief Tech/Sci/R&D Officer | |
Alnara Pharmaceuticals, Inc.
 Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| University of Glasgow | College/University | Graduate Degree Undergraduate Degree | |
BDC Venture Capital
 BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Investment Managers | Director/Board Member Head-Equity Investments Private Equity Investor | |
BHP Coated Steel Corp
 BHP Coated Steel Corp SteelNon-Energy Minerals Part of Ternium SA, BHP Coated Steel Corp produces cold-rolled, metallic-coated and custom-painted steel coils for the construction and OEM markets. The private company is based in Kalama, WA. BHP Coated Steel was acquired by IMSA Acero SA de CV on May 25, 2000 for $234 million. | Steel | Director of Finance/CFO | |
| Queen's University | College/University | Graduate Degree | |
| PROMIS NEUROSCIENCES, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| San Diego State University | College/University | Undergraduate Degree | |
| The University of Texas at Austin | College/University | Doctorate Degree | |
| University of British Columbia | College/University | Doctorate Degree | |
| University of Toronto | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| The University of Waterloo | College/University | Graduate Degree | |
| University of Western Ontario | College/University | Masters Business Admin Doctorate Degree Undergraduate Degree | |
| University of Kentucky | College/University | Doctorate Degree | |
| University of Maryland | College/University | Doctorate Degree | |
Agrisoma Biosciences, Inc.
 Agrisoma Biosciences, Inc. Chemicals: SpecialtyProcess Industries Agrisoma Biosciences, Inc. provides crop technology for biofuel and renewable energy solutions. Its crop improvement technologies include proprietary breeding, proprietary tissue culture and haploidy, molecular markers and genetic mapping and advanced crop improvement technologies. The company was founded by Steven Fabijanski and Tom Mamic in 2001 and is headquartered in Gatineau, Canada. | Chemicals: Specialty | Director/Board Member | |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Chief Executive Officer Director/Board Member | |
UCB Pharma, Inc.
 UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Pharmaceuticals: Major | Director/Board Member | |
TaiGen Biotechnology Co., Ltd.
 TaiGen Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| West China University of Medical Sciences | College/University | Graduate Degree | |
Interface Biologics, Inc.
 Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Information Technology Services | Director/Board Member Director/Board Member | |
Crohn's & Colitis Foundation of America
 Crohn's & Colitis Foundation of America Miscellaneous Commercial ServicesCommercial Services Crohn's & Colitis Foundation of America is a non-profit organization that is run by volunteers. The non-profit company is based in New York, NY and has subsidiaries in the United States. The organization is dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. The CEO of the company is Richard J. Geswell. | Miscellaneous Commercial Services | Chairman | |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Pan-American College (Texas) | College/University | Undergraduate Degree | |
| University of Texas at San Antonio | College/University | Doctorate Degree | |
| FRONTIER BIOTECHNOLOGIES INC. | Biotechnology | Founder | |
Rna Diagnostics, Inc.
 Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada. | Medical Specialties | Director/Board Member |
Statistik
International
| Kanada | 24 |
| Vereinigte Staaten | 19 |
| Vereinigtes Königreich | 6 |
| China | 3 |
| Taiwan | 2 |
Sektoral
| Health Technology | 24 |
| Consumer Services | 14 |
| Finance | 5 |
| Commercial Services | 3 |
| Producer Manufacturing | 2 |
Operativ
| Director/Board Member | 71 |
| Corporate Officer/Principal | 47 |
| Director of Finance/CFO | 19 |
| Chairman | 18 |
| Chief Tech/Sci/R&D Officer | 16 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Timothy Morris | 21 |
| Michael Berendt | 20 |
| Michael G. Moore | 16 |
| Michael B. Cross | 15 |
| Graham Strachan | 15 |
| Ela Borenstein | 13 |
| Lily Lam | 11 |
| Hermanth Varghese | 11 |
| James Parsons | 10 |
| Barbara Troupin | 9 |
| Denis Ho | 9 |
| Thomas Rowland | 8 |
| Michael J. Gresser | 7 |
| Craig Binnie | 6 |
| Chang Jin Wang | 6 |
- Börse
- Insiders
- John Dietrich
- Unternehmensverbindungen
